The Phox Homology (PX) domain-dependent, 3-phosphoinositide-mediated association of sorting nexin-1 with an early sorting endosomal compartment is required for its ability to regulate epidermal growth factor receptor degradation by Cozier, G. E. et al.
The Phox Homology (PX) Domain-dependent, 3-Phosphoinositide-
mediated Association of Sorting Nexin-1 with an Early Sorting
Endosomal Compartment Is Required for Its Ability to Regulate
Epidermal Growth Factor Receptor Degradation*
Received for publication, July 12, 2002, and in revised form, August 22, 2002
Published, JBC Papers in Press, August 26, 2002, DOI 10.1074/jbc.M206986200
Gyles E. Cozier‡§, Jez Carlton‡§¶, Alex H. McGregor‡, Paul A. Gleeson, Rohan D. Teasdale**,
Harry Mellor‡‡§§, and Peter J. Cullen‡¶¶
From the ‡Inositide Group, Henry Wellcome Integrated Signalling Laboratories, Department of Biochemistry, School of
Medical Sciences, University of Bristol, Bristol BS8 1TD, United Kingdom, ‡‡Department of Biochemistry, School of
Medical Sciences, University of Bristol, Bristol BS8 1TD, United Kingdom, Department of Biochemistry and Molecular
Biology, University of Melbourne, Victoria 3010, Australia, and the **Institute for Molecular Bioscience, Ritchie Building,
Research Road, The University of Queensland, St. Lucia, Brisbane 4072, Australia
Recent studies have shown that phox homology (PX)
domains act as phosphoinositide-binding motifs. The
majority of PX domains studied show binding to phos-
phatidylinositol 3-monophosphate (PtdIns(3)P), an asso-
ciation that allows the host protein to localize to mem-
branes of the endocytic pathway. One issue, however, is
whether PX domains may have alternative phosphoi-
nositide binding specificities that could target their
host protein to distinct subcellular compartments or
allow their allosteric regulation by phosphoinositides
other than PtdIns(3)P. It has been reported that the PX
domain of sorting nexin 1 (SNX1) specifically binds
phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)-
P3) (Zhong, Q., Lazar, C. S., Tronchere, H., Sato, T.,
Meerloo, T., Yeo, M., Songyang, Z., Emr, S. D., and Gill,
G. N. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 6767–6772).
In the present study, we have shown that whereas SNX1
binds PtdIns(3,4,5)P3 in protein:lipid overlay assays, in
liposomes-based assays, binding is observed to PtdIns-
(3)P and phosphatidylinositol 3,5-bisphosphate (PtdIns-
(3,5)P2) but not to PtdIns(3,4,5)P3. To address the signif-
icance of PtdIns(3,4,5)P3 binding, we examined the sub-
cellular localization of SNX1 under conditions in which
plasma membrane PtdIns(3,4,5)P3 levels were signifi-
cantly elevated. Under these conditions, we failed to
observe association of SNX1 with this membrane. How-
ever, consistent with the binding to PtdIns(3)P and
PtdIns(3,5)P2 being of more physiological significance
was the observation that the association of SNX1 with
an early endosomal compartment was dependent on a
3-phosphoinositide-binding PX domain and the pres-
ence of PtdIns(3)P on this compartment. Finally, we
have shown that the PX domain-dependent/early endo-
somal association of SNX1 is important for its ability to
regulate the targeting of internalized epidermal growth
factor receptor for lysosomal degradation.
The membrane phospholipid phosphatidylinositol is the pre-
cursor for a family of lipid second messengers, known collec-
tively as phosphoinositides, that differ solely in the phospho-
rylation status of their inositol head group (1, 2).
Phosphoinositides are ideally suited to function as spatially
restricted membrane second messengers because: the synthesis
and turnover of phosphoinositides from the relatively abun-
dant phosphatidylinositol precursor can be rapid and highly
concentrated within discrete membrane micro-domains; the
ratio of phosphoinositide to binding partner can be relatively
large, which makes it possible to target a large number of
distinct proteins to a particular membrane without saturating
the binding sites; structurally distinct phosphoinositides can
activate distinct downstream effectors; and the potential for
rapid, sequential interconversion between phosphorylated
forms means that phosphoinositides can confer processivity to
membrane signaling events (reviewed in Refs. 3–5).
A major advance in our understanding of phosphoinositide
signaling has been the identification of a number of highly
conserved modular protein domains that bind various phos-
phoinositides. To date, a number of distinct phosphoinositide-
binding motifs have been identified and characterized includ-
ing the epsin amino-terminal homology (ENTH) domain, Fab1,
YOTB, Vac1, and EEA1 (FYVE) domain, band 4.1, ezrin, radixin,
and moesin (FERM) domain, pleckstrin homology domain, and
more recently, the phox homology (PX)1 domain (reviewed in
Refs. 4–8). Such “cut and paste” modules are found in a diverse
array of multidomain proteins and recruit their host protein to
specific subcellular compartments via their interaction with
phosphoinositides. They may also serve as allosteric regulators of
enzyme activity and protein-protein interactions.
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The PX domain was initially identified as a conserved motif
of130 residues within the p40phox and p47phox subunits of the
neutrophil NADPH oxidase superoxide-generating complex (9).
PX domains can be found in a wide variety of proteins involved
in cell signaling (phospholipase D1 and D2, class II phosphoi-
nositide 3-kinases), control of yeast bud emergence and polarity
(Bem1p and Bem3p), and vesicle trafficking (human sorting
nexins, yeast Vam7p). Currently, at least 57 human and 15
yeast proteins that contain PX domains have been identified
(reviewed in Refs. 5 and 10–14).
Recent simultaneous studies from a number of laboratories
have now shown that several PX domains act as specific phos-
phoinositide-binding motifs (15–24). The majority of PX do-
mains studied so far show binding selectivity to phosphatidy-
linositol 3-monophosphate (PtdIns(3)P); indeed, all yeast PX
domains have been reported to recognize this lipid (23). In
those cases in which it has been studied, the ability of the PX
domain to bind PtdIns(3)P results in the association of the host
protein with components of the endocytic pathway. In this
respect, PX domains resemble FYVE domains, although the
two are structurally distinct (25–27).
One key issue, however, is whether PX domains may have
alternative phosphoinositide binding specificities that could
target their host protein to distinct subcellular compartments
or allow their allosteric regulation by phosphoinositides other
than PtdIns(3)P. It has recently been reported that the PX
domain of sorting nexin 1 (SNX1) does not bind PtdIns(3)P but
rather specifically binds phosphatidylinositol 3,4,5-trisphos-
phate (PtdIns(3,4,5)P3) (28). In this present study, we have
shown that SNX1 may not bind PtdIns(3,4,5)P3 in vivo; rather,
its PX domain binds with similar affinities PtdIns(3)P and
phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2). Such a
conclusion is entirely consistent with the PX domain-depend-
ent, phosphoinositide-induced association of SNX1 with an
early endosomal compartment, an association that is important
for the ability of SNX1 to regulate EGF receptor traffic.
EXPERIMENTAL PROCEDURES
Antibodies—Anti-SNX1 and anti-EEA1 mouse monoclonal antibod-
ies were from BD Biosciences. Anti-ARNO mouse monoclonal was from
Sigma. Anti-CD63 mouse monoclonal antibody was from Biogenesis.
Mouse anti-EGF receptor monoclonal antibody and rabbit anti-LAMP1
polyclonal antibody were kind gifts from Professor Peter Parker (Can-
cer UK, London, England) and Professor Colin Hopkins (Imperial Col-
lege, London, England).
Cloning and Site-directed Mutagenesis—Eukaryotic expression plas-
mids carrying the entire coding region of SNX1 were as described
previously (30). For bacterial expression, the SNX1 coding region was
cloned into pGEX4T-3 (30). Site-directed mutagenesis was performed as
described previously (29) using the Transformer kit (Clontech).
Protein-Lipid Overlay Assay—Protein-lipid overlay assays were
based on the procedure described by Dowler et al. (31). Membrane
arrays were generated by spotting the required mass of the indicated
phosphoinositide (Cell Signals, Inc.) onto a Hybond-C extra membrane.
After air drying and blocking in 3% (w/v) fatty acid-free bovine serum
albumin in 10 mM Tris/HCl, pH 8.0, 150 mM NaCl, and 0.1% (v/v) Tween
20 (Tris-buffered saline), the membrane was incubated overnight at
4 °C in the same solution containing 0.5 g/ml of the relevant recom-
binant protein. The membrane was extensively washed in Tris-buffered
saline and then incubated with either an anti-SNX1 or an anti-ARNO
monoclonal antibody. The membrane was washed as before, prior to
being incubated with anti-mouse horseradish peroxidase conjugate.
Finally, the membrane was again extensively washed, and protein
associated with the various phosphoinositides was visualized using
enhanced chemiluminescence.
Sucrose-loaded Liposome Assays—Lipid mixtures of phosphati-
dylethanolamine, phosphatidylcholine, and phosphatidylserine were sup-
plemented with the required ratio of phosphatidylinositol and the rele-
vant diC16 phosphoinositide (Cell Signals, Inc) prior to being dried down
to form a film in a 0.5-ml minifuge tube (Beckman Coulter Inc.). The
subsequent formation of sucrose-loaded liposomes and the analysis of
recombinant SNX1 binding were performed as described previously (29).
Transient Transfection and Cell Imaging—HeLa and PC12 cells,
cultured as described (29, 32), were plated on glass coverslips and
transfected with vector DNA at 50–60% confluence by lipofection using
LipofectAMINE (Invitrogen) at a ratio of 0.15 g of DNA/l of cationic
lipid. At the designated period after transfection, cells were either fixed
using paraformaldehyde (4% (w/v) for 5 min at room temperature) or
used live for biochemical or imaging studies. Indirect immunofluores-
cence was performed on fixed cells permeabilized with 0.1% Triton
X-100 for 10 min at room temperature using a Leica TCS-NT confocal
microscope equipped with a krypton/argon laser as described previously
(33). Live cell imaging was performed using an UltraView MultiUser
Confocal Optical Scanner (PerkinElmer Life Sciences) as described
previously (32).
EGF Receptor Degradation Assays—HeLa cells transiently trans-
fected with the relevant SNX1 construct were serum-starved overnight
prior to addition of EGF (100 ng/ml). At the required time point, cells
were fixed with 4% (w/v) paraformaldehyde for 5 min at room temper-
ature and permeabilized by incubation with 0.1% Triton X-100 for 10
min at room temperature. Endogenous EGF receptor was visualized by
incubation with anti-EGF receptor antibody. The amount of EGF re-
ceptor within a single cell was quantified by confocal imaging. In blind
experiments, groups of cells were imaged, and the pixel intensity of the
EGF receptor fluorescent signal within an area defined by the outer
limits of the plasma membrane was calculated using the Leica TCS-
NT4 software.
RESULTS
In Protein-Lipid Overlay Assays, the PX Domain of SNX1
Specifically Binds PtdIns(3,4,5)P3—Given the precedent set by
the specific binding of PtdIns(3)P to the PX domain of SNX3
(15), we examined whether SNX1 was also capable of interact-
ing with phosphoinositides. To assess the phosphoinositide
binding properties of recombinant full-length SNX1, we ini-
tially made use of a protein-lipid overlay (33–35). This assay,
which is being increasingly used as a standard method for
analyzing phosphoinositide binding profiles (e.g. see Refs. 20,
21, 23, and 28), relies upon spotting varying amounts of pure
lipid onto a nitrocellulose membrane. Once dry, the membrane
is incubated with the protein of interest and, after extensive
washing, the interaction of the protein with any phosphoinosi-
tide is detected by immunoblotting. As shown in Fig. 1A, under
these conditions, full-length recombinant SNX1 bound
PtdIns(3,4,5)P3 with no significant binding being observed to
any other phosphoinositide. Such a phosphoinositide binding
profile is similar to that observed for the well characterized
PtdIns(3,4,5)P3-binding pleckstrin homology domain of the
ARF6 exchange factor ARNO (Fig. 1B; see also Ref. 36). Indeed,
the affinity for PtdIns(3,4,5)P3 appears similar for each protein
(data not shown).
Sequence homology between PX domains is generally low,
highlighted by the identity between p40phox and SNX1 PX
domains being just 13%. However, a comparison of the p40phox
and SNX1 PX domains sequences shows that all but one of the
residues required for PtdIns(3)P binding to p40phox is con-
served (or has a structurally equivalent alternative) in the
SNX1 PX domain (Fig. 1C). The major residues in the binding
site of the p40phox PX domain-PtdIns(3)P complex that interact
with the PtdIns(3)P are Tyr-59 and the basic residues Arg-58,
Arg-60, Lys-92, and Arg-105 (25). Tyr-59 forms a stacking
interaction with the PtdIns(3)P ring, whereas the basic resi-
dues interact with the phosphates and hydroxyls (Arg-58 and
Arg-60 with the 3-phosphate, Lys-92 with the 1-phosphate, and
Arg-105 with the 4- and 5-hydroxyls). Only Arg-60 is not con-
served (Ser-188 in SNX1); Tyr-59 of p40phox is replaced with
Phe-187 in SNX1 and therefore retains the aromatic ring struc-
ture. Also, a proline-rich region and a structurally important
arginine (Arg-57 in p40phox and Arg-185 in SNX1) are con-
served. To examine the importance of the PX domain in the
association of SNX1 with PtdIns(3,4,5)P3, we therefore mu-
tated the lysine residues at position 214 to alanine (K214A). As
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shown in Fig. 1D, SNX1(K214A) failed to associate with
PtdIns(3,4,5)P3, an observation entirely consistent with a role
for the PX domain in the binding to this phosphoinositide.
In Liposome-based Assays, the PX Domain of SNX1 Does Not
Bind PtdIns(3,4,5)P3, Rather Association with PtdIns(3)P and
PtdIns(3,5)P2 Is Observed—To perform a more physiologically
relevant phosphoinositide binding analysis, we generated su-
crose-loaded liposomes composed of a mixture of phosphatidyl-
serine, phosphatidylethanolamine, and phosphatidylcholine
(each at 26.3% (w/w)) to which was added 20% (w/w) of PtdIns,
PtdIns(3)P, PtdIns(4)P, PtdIns(5)P, PtdIns(3,4)P2, PtdIns(4,5)-
P2, PtdIns(3,5)P2, or PtdIns(3,4,5)P3 (total lipid content within
the assay of 70 M). Under these conditions, although binding
of ARNO to PtdIns(3,4,5)P3-containing liposomes was clearly
detected (data not shown), we failed to observe any binding of
recombinant SNX1 to liposomes supplemented with PtdIns-
(3,4,5)P3 (Fig. 2A). Rather, binding was clearly detectable to
liposomes that had been supplemented with PtdIns(3)P or
PtdIns(3,5)P2. No significant binding was detected to any of the
other phosphoinositides (Fig. 2A). To obtain the relative affin-
ity of SNX1 for these two phosphoinositides, we sequentially
lowered PtdIns(3)P and PtdIns(3,5)P2 levels but maintained
the same total lipid content by increasing the mass of PtdIns
(Fig. 2B). Under these conditions, SNX1 displayed a similar
affinity for PtdIns(3)P and PtdIns(3,5)P2, having an apparent
association constant (assuming an even distribution of the lip-
ids within the aqueous environment) of 1.1  0.3 and 3.1  0.7
M, respectively. Binding was via the SNX1 PX domain since
SNX1(K214A) failed to associate with either PtdIns(3)P or
PtdIns(3,5)P2 (Fig. 2C).
3-Phosphoinositide Binding to the PX Domain Is Necessary
for the Targeting of SNX1 to an Early/Sorting Endosomal
Compartment—To examine the relationship between phospho-
inositide binding and the resultant subcellular localization of
SNX1, we initially examined the localization of endogenous
SNX1 in HeLa cells. This revealed that SNX1 was predomi-
nantly localized to punctate cytoplasmic structures (Fig. 3A). A
similar subcellular localization was also observed in HeLa cells
transiently transfected with wild-type SNX1 tagged with green
fluorescent protein (GFP) (Fig. 3B). To more precisely define
the nature of the SNX1-positive compartment, we probed HeLa
cells expressing GFP-SNX1 with antibodies against various
markers of the endocytic pathway, including early endosomal
antigen 1 (EEA1) and the late endosomal/lysosomal markers
LAMP1/lgp120 and CD63. Under these conditions, SNX1
FIG. 1. SNX1 binds specifically PtdIns(3,4,5)P3 in lipid-overlay
assays. The ability of SNX1 (A), ARNO (B) , and SNX1(K214A) (D) to
bind a variety of phosphoinositides was analyzed using a protein-lipid
overlay assay. 100 pmol of the relevant phosphoinositide was spotted
onto a nitrocellulose membrane, which was then incubated with the
purified proteins. The membranes were washed, and proteins bound to
the membrane by virtue of their interaction with lipid were detected
using specific antibodies. A representative of at least three separate
experiments is shown. C, the sequence homology between the p40phox
and SNX1 PX domains, highlighting the highly conserved nature of the
residues required for PtdIns(3)P binding to p40phox within the SNX1 PX
domain and the lysine residue mutated in this study. The secondary
structural elements from p40phox are shown in bold. FIG. 2. SNX1 binds both PtdIns(3)P (PI(3)P) and PtdIns(3,5)P2
(PI(3,5)P2) in liposome-based assays. In A, to dried-down phos-
phatidylserine, phosphatidylcholine, and phosphatidylethanolamine
(each at 26.3% (w/w)) was added 20% (w/w) of the relevant phospho-
inositide (total lipid content within the assay of 70 M). Sucrose-loaded
liposomes, formed as described under ‘Experimental Procedures,‘ were
incubated with 250–500 ng of recombinant SNX1 for 4 min at 30 °C.
The resultant SNX1-lipid complexes were pelleted by centrifugation,
and the resultant supernatants (S) and pellets (P) were separated prior
to being resolved by SDS-PAGE and Western blotting using SNX1-
specific antisera. In B, to dried-down phosphatidylserine, phosphatidyl-
choline, and phosphatidylethanolamine (each at 26.3% (w/w)) was
added the relevant amount of PtdIns(3)P or PtdIns(3,5)P2. The total
lipid content within the assay was maintained at 70 M by the addition
of PtdIns. PtdIns(3)P and PtdIns(3,5)P2 binding was quantified from
Western blots by volume integration using ImageQuaNT software (ver-
sion 3.3, Molecular Dynamics Inc). Data from three separate experi-
ments were used to determine the association constants of SNX1 for the
two phosphoinositides (see ‘Results‘). In C, to dried-down phosphatidyl-
serine, phosphatidylcholine, and phosphatidylethanolamine (each at
26.3% (w/w)) was added 20% (w/w) of the relevant phosphoinositide
(total lipid content within the assay of 70 M). Sucrose-loaded lipo-
somes, formed as described above, were incubated with 250–500 ng of
recombinant SNX1(K214A) for 4 min at 30 °C. The resultant SNX1/
lipid complexes were pelleted by centrifugation, and the resultant su-
pernatants (S) and pellets (P) were separated prior to being resolved by
SDS-PAGE and Western blotting using SNX1-specific antisera.
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showed substantial, but not complete, co-localization with
EEA1 (Fig. 4). There was substantially less co-localization with
late endosomal and lysosomal markers. Thus, as documented
previously (24, 30, 37–39), SNX1 appears to be partially local-
ized to the early endosomal compartment.
In contrast to GFP-SNX1, GFP-SNX1(K214A) was entirely
present within the cytoplasm (Fig. 5A). Given that wild-type
SNX1 is capable of binding phosphoinositides, a function not
retained by SNX1(K214A), these data are entirely consistent
with a requirement for 3-phosphoinositide binding to the PX
domain for the targeting of SNX1 to the early endosomal com-
partment. Further evidence in favor of this came from the
observation that following the addition of wortmannin (100 nM
for 15 min), wild-type SNX1 underwent dissociation from this
compartment (Fig. 5B).
SNX1 Does Not Associate with the Plasma Membrane under
Conditions in which Plasma Membrane PtdIns(3,4,5)P3 Is El-
evated—Although the data described above highlight the im-
portance of 3-phosphoinositide binding to the PX domain for
the association of SNX1 with the early endosomal compart-
ment, these data fail to address whether this association is
because of the interaction with PtdIns(3)P, PtdIns(3,5)P2,
and/or PtdIns(3,4,5)P3. Work form a number of groups, includ-
ing ourselves, has shown that the major site of PtdIns(3,4,5)P3
production is the inner leaflet of the plasma membrane (40–
42). For example, in PC12 cells expressing a GFP-tagged di-
glycine ARNO chimera (GFP-ARNO), live cell confocal imaging
has revealed that following stimulation with an agonist that
elevates PtdIns(3,4,5)P3, cytosolic GFP-ARNO undergoes a
rapid recruitment to the plasma membrane (Fig. 6A). This
recruitment results from the pleckstrin homology domain of
ARNO directly binding PtdIns(3,4,5)P3 generated at the inner
plasma membrane leaflet (36). Thus, if the binding of the SNX1
PX domain to PtdIns(3,4,5)P3 observed in lipid overlay assays
is physiologically relevant, one would predict that SNX1 should
FIG. 3. SNX1 is localized to punctate cytoplasmic structures.
HeLa cells were stained for endogenous SNX1 (1:200 primary antibody)
(A) or transiently transfected with pEGFP-SNX1 (B). Cells were fixed
and mounted, and the localization of SNX1 was visualized by confocal
microscopy. The scale bar is 10 m.
FIG. 4. SNX1 is localized to an early sorting endosomal com-
partment. HeLa cells were transiently transfected with pEGFP-SNX1
and incubated for 12 h prior to fixation. Permeabilized cells were
subsequently stained for the presence of EEA1 (1:200), CD63 (1:200),
and Lamp1 (1:200) using a Cy3-conjugated secondary antibody prior to
visualization of the degree of co-localization by confocal microscopy. The
scale bar is 10 m.
FIG. 5. Association of SNX1 with the early sorting endosomal
compartment requires a 3-phosphoinositide-binding PX domain
and the activity of a wortmannin-sensitive phosphatidylinositol
3-kinase. In A, HeLa cells were transiently transfected with pEGFP-
SNX1(K214A) and incubated for 12 h prior to fixation. In B, HeLa cells,
transiently transfected with pEGFP-SNX1, were cultured for 12 h and
then incubated for 15 min with 100 nM wortmannin prior to fixation.
The scale bar is 10 m.
FIG. 6. SNX1 does not associate with the plasma membrane
following elevation of PtdIns(3,4,5)P3. PC12 cells were transiently
transfected with pEGFP-ARNO (A) and pEGFP-SNX1 (B). In C and D,
cells were transiently co-transfected with a vector encoding for
p110CAAX and pEGFP-ARNO or pEGFP-SNX1 respectively. In all cases,
cells were serum-starved for 2 h prior to treatment. In A and B, cells
were stimulated with 100 ng/ml EGF immediately after capture of the
t  0 image. Images were captured every 10 s for a period of 5 min. For
clarity, only the images collected after 60 s of stimulation are shown.
Similar data were obtained from a further 15 imaged cells. In C and D,
cells were imaged without stimulation. The scale bar is 10 m.
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associate with the inner leaflet of the plasma membrane. Al-
though in HeLa cells we have failed to observe any association
of GFP-SNX1 to this membrane prior to or after stimulation
with growth factors that elevate plasma membrane PtdIns-
(3,4,5)P3 (data not shown), we have used the observation that
in PC12 cells expressing GFP-SNX1, a significant proportion of
the GFP-SNX1 is located in a cytoplasmic pool to address this
issue more directly (Fig. 6B). Under these conditions, we failed
to observe any plasma membrane recruitment of GFP-SNX1
following stimulation of PC12 cells with either maximal doses
of EGF or maximal doses of nerve growth factor (Fig. 6B).
Finally, in PC12 cells transiently co-transfected with GFP-
SNX1 and p110CAAX, a constitutively active version of phos-
phatidylinositol 3-kinase that induces a basal elevation in
plasma membrane PtdIns(3,4,5)P3 levels (36), GFP-SNX1 re-
mained cytosolic, whereas in control experiments, GFP-ARNO
was clearly constitutively associated with the plasma mem-
brane (Fig. 6, C and D). When taken together, such data raise
doubt as to the whether in an SNX1 does indeed bind
PtdIns(3,4,5)P3 in vivo context.
SNX1 Partially Co-localizes with a Specific PtdIns(3)P Probe—
To assess the relationship between SNX1 and the subcellular
distribution of PtdIns(3)P, we transiently transfected HeLa cells
with constructs encoding for SNX1 and GFP-2xFYVEhrs, a spe-
cific probe for PtdIns(3)P (43, 44). As shown in Fig. 7, confocal
microscopy revealed a partial co-localization of SNX1 with the
PtdIns(3)P probe. These data, when taken with the evidence from
the liposome assays, strongly imply that the association of SNX1
with the early endosomal compartment results from the ability of
its PX domain to bind PtdIns(3)P.
3-Phosphoinositide-dependent Association of SNX1 with an
Early Endosomal Compartment Is Required for the Regulation
of EGF Receptor Degradation—SNX1 was originally isolated in
a yeast two-hybrid screen through its ability to interact with
the lysosomal-targeting signal of the EGF receptor (37). This
has led to the suggestion that SNX1 may play a role in target-
ing the EGF receptor for lysosomal degradation through the
endocytic pathway. Indeed, overexpressed SNX1 decreases the
amount of EGF receptor by enhancing the rate of ligand-in-
duced degradation (28, 37, 38). In HeLa cells, within 10 min of
stimulation with EGF, the EGF receptor is clustered and in-
ternalized into small vesicles corresponding to early endosomes
(45). The receptor reaches larger perinuclear structures by 30
min with some loss of signal at 60 min as the receptor begins to
reach the lysosomal compartment and is degraded (45). By 120
min, few EGF receptor-positive structures remain, owing to
lysosomal degradation of the signal (45). To examine the func-
tional consequence of 3-phosphoinositide-dependent associa-
tion of SNX1 with the early endosomal compartment, we ana-
lyzed the degradation of endogenous EGF receptor using a
single cell assay. In this assay, we quantified, as a function of
time after EGF addition, the pixel intensity of the EGF recep-
tor-positive signal within a region of interest that was defined
by the plasma membrane. Using this assay, we could compare
the effect of overexpressing SNX1 and SNX1(K214A) on EGF
receptor degradation. In control cells, we observed a decrease
in EGF receptor signal following the addition of EGF (Fig. 8).
Furthermore, entirely consistent with previous studies on
SNX1, in cells overexpressing wild-type SNX1, there was a
small but clear enhancement in the rate of EGF receptor deg-
radation (Fig. 8). In contrast, in those SNX1(K214A)-overex-
pressing cells, no increase in the rate of EGF receptor degra-
dation was observed (Fig. 8). These data suggest, therefore,
that the PX domain-induced, 3-phosphoinositide-dependent as-
sociation of SNX1 with an early endosomal compartment is
required to regulate the lysosomal traffic and degradation of
the internalized EGF receptor.
DISCUSSION
In the present study, we have analyzed the phosphoinositide
binding profile of the PX domain from SNX1 using two distinct
techniques, protein-lipid overlays, a simple and extremely
rapid assay, and liposome binding assays, a more physiological
relevant but technically demanding assay. Consistent with the
study of Zhong et al. (28), we have shown that in the overlay
assay, the PX domain of SNX1 appears to specifically bind
PtdIns(3,4,5)P3. However, when phosphoinositide binding was
determined using the liposome-based assay, we failed to detect
any binding to PtdIns(3,4,5)P3; rather, high affinity binding
was observed to PtdIns(3)P and PtdIns(3,5)P2. Why the mode of
presenting the phosphoinositide substrate should have such a
dramatic bearing on the binding profile of the SNX1 PX domain
is currently unclear. However, our data do raise an important
issue. Evidence presented here would imply that using just the
protein-lipid overlay assays to obtain a phosphoinositide bind-
ing profile for a given protein should not be viewed as an
altogether reliable approach. Rather, evidence from at least
two independent assays should be obtained to define a phos-
phoinositide binding profile.
In an attempt to address which interaction with 3-phosphoi-
nositides may be more physiologically relevant, we examined
the subcellular localization of SNX1. Consistent with other
studies (28, 39), we observed that SNX1 was associated with
FIG. 7. The SNX1-positive compartment partially co-localizes
with a probe for PtdIns(3)P. HeLa cells were transiently co-trans-
fected with pEGFP-2xFYVEhrs and pCIneo-SNX1 and incubated for
12 h prior to fixation. Permeabilized cells were subsequently stained for
the presence of SNX1 (1:200) prior to visualization of the degree of
co-localization by confocal microscopy. The scale bar is 10 m.
FIG. 8. Overexpression of SNX1, but not SNX1(K214A), leads to
a stimulation in the degradation of the EGF receptor (EGFR).
HeLa cells, transiently transfected with pEGFP, pEGFP-SNX1, or
pEGFP-SNX1(K214A), were cultured for 24 h. Cells were serum-
starved overnight prior to being stimulated with EGF (100 ng/ml) for
the required time period. Cells were fixed and stained for EGF receptor.
The amount of EGF fluorescent signal was determined as described
under ‘Experimental Procedures.‘ Data are averaged  S.E. for not less
then 75 cells imaged under each condition.
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intracellular vesicles that showed a partial overlap with the
EEA1-positive early endosomal compartment. We failed to ob-
serve any association of SNX1 with the plasma membrane, the
major site of PtdIns(3,4,5)P3 synthesis (40–42), either after
stimulation with agonists that elevate PtdIns(3,4,5)P3 or in
experiments in which we elevated basal PtdIns(3,4,5)P3 levels
by co-expressing SNX1 with a constitutively active class I phos-
phatidylinositol 3-kinase. Under all of these conditions, how-
ever, we observed a clear plasma membrane association of the
well characterized PtdIns(3,4,5)P3-binding protein ARNO, the
pleckstrin homology domain of which binds PtdIns(3,4,5)P3
with a similar affinity to the SNX1 PX domain (32). These data
would therefore argue against the idea that the binding of
PtdIns(3,4,5)P3 to the PX domain of SNX1 is required for its
association with the SNX1-positive endosomal compartment.
Furthermore, it raises the issue of whether the binding of
PtdIns(3,4,5)P3 to the PX domain of SNX1 observed using the
overlay assays is of any physiological relevance.
The association of SNX1 to the early endosomal compart-
ment was clearly dependent on the ability of its PX domain to
bind 3-phosphoinositides since firstly, a point mutant,
SNX1(K214A), incapable of binding 3-phosphoinositides local-
ized to the cytosol, and secondly, wild-type SNX1 could be
dissociated from the early endosomal compartment by incuba-
tion with the phosphatidylinositol 3-kinase inhibitor wortman-
nin. Such data, when taken together with the partial co-local-
ization of SNX1 with a probe that reveals the subcellular
localization of PtdIns(3)P, are certainly more easily explained
by the binding of the SNX1 PX domain to endosomal
PtdIns(3)P being necessary for the targeting of this protein to
the early endosomal compartment.
The physiological importance of the interaction of SNX1 with
3-phosphoinositides has been highlighted through an analysis
of the role of SNX1 in the regulation of EGF receptor degrada-
tion. We have shown that whereas wild-type SNX1 is capable of
stimulating the rate of EGF receptor degradation, this is not
achieved with the SNX1(K214A) mutant. Thus, the PtdIns(3)P-
dependent, PX domain-mediated association of SNX1 with an
early endosomal compartment is necessary for the ability of
this protein to target the EGF receptor for lysosomal degrada-
tion through the endocytic pathway (28, 37).
One outstanding issue, however, concerns the physiological
relevance of PtdIns(3,5)P2 binding to the SNX1 PX domain.
Studies in Saccharomyces cerevisiae have highlighted a role for
PtdIns(3,5)P2 in yeast membrane traffic (46–48). The major
phenotypic characteristics resulting from inactivation of yeast
fab1, whose gene product encodes for the PtdIns(3)P 5-kinase
that produces PtdIns(3,5)P2, include severe growth defects and
extremely enlarged vacuoles that occupy the majority of the cell
(48). Despite these defects, however, all transport pathways to
the vacuole in Fab1p-deficient cells appear intact (49), suggest-
ing that Fab1p kinase and PtdIns(3,5)P2 function to maintain
vacuolar size and membrane homeostasis by regulating recy-
cling/turnover of membranes from the yeast vacuole surface to
earlier compartments. Consistent with PtdIns(3,5)P2 playing a
role in endocytic membrane homeostasis has been the observa-
tion that overexpression of a kinase-deficient point mutant of
PIKfyve, the mammalian ortholog of Fab1p (50–53), leads to
the formation of multiple swollen endosomal vacuoles in a
number of different mammalian cells (54). In contrast with our
understanding of the role of PtdIns(3)P in endosomal traffic
that has arisen from the identification of PtdIns(3)P effectors
(55), our understanding of PtdIns(3,5)P2 is hampered by the
lack of identified effectors for this lipid. Indeed, at present, no
PtdIns(3,5)P2 effectors have been described. In light of the data
presented here, it is tempting to speculate that SNX1 may
constitute such an effector molecule, allowing PtdIns(3,5)P2 to
regulate endosomal to lysosomal membrane traffic.
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